戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 mersen, and 47% (95% CI, 21% to 73%) without oblimersen.
2 ggested worse outcome for patients receiving oblimersen.
3 red intravenously for 3 days with or without oblimersen 3 mg/kg/d as a 7-day continuous intravenous i
4      Notably, we improved the performance of Oblimersen, a BCL-2 ASO drug that failed in phase-III cl
5 he current clinical information available on oblimersen, a novel antisense approach targeting Bcl-2 i
6 e, bevacizumab, ZD6474, imatinib, gefitinib, oblimersen and aplidine have all entered clinical trial
7  at 1 year was 24% (95% CI, 12% to 40%) with oblimersen, and 47% (95% CI, 21% to 73%) without oblimer
8 f the Bcl-2 oncoprotein can be achieved with oblimersen (antisense molecule specific for Bcl-2).
9 platin and etoposide with (arm A) or without oblimersen (arm B) in 56 assessable patients with chemot
10 a and thrombocytopenia were increased in the oblimersen-dacarbazine group; however, there was no incr
11  achieved in 20 (17%) of 120 patients in the oblimersen group and eight (7%) of 121 patients in the c
12           Phase I and phase II studies using oblimersen in combination with conventional chemotherapy
13 l trials have shown single-agent activity of oblimersen in patients with chronic lymphocytic leukemia
14 rials will establish the clinical utility of oblimersen in patients with hematologic malignancies.
15 y agents, proapoptotic small molecules (e.g. oblimersen, obatoclax, and gossypol), antifols (e.g. pra
16                     Plasma concentrations of oblimersen (parent drug) and its major metabolites were
17                        A randomized trial of oblimersen plus fludarabine/cyclophosphamide (OBL-FC; n
18                                      (+)-JQ1-Oblimersen showed increased effectiveness in an acute my
19 seline serum LDH and treatment was observed; oblimersen significantly increased survival in patients
20 reated elderly AML patients by administering oblimersen sodium (G3139), an 18-mer phosphorothioate an
21                                              Oblimersen sodium has modest single-agent activity in he
22                                  Dosing with oblimersen sodium in patients with CLL is limited by dev
23 ng Bcl-2 using an antisense oligonucleotide (oblimersen sodium) could improve the efficacy of systemi
24                  Bcl-2 suppression by G3139 (oblimersen sodium), a phosphorothioate oligonucleotide c
25 s such as bortezomib, perifosine, atacicept, oblimersen sodium, and tositumomab show promise as ratio
26 cl-2 in chemoresistance in SCLC, addition of oblimersen to a standard regimen for this disease did no
27                              The addition of oblimersen to dacarbazine significantly improved multipl
28  patients randomly assigned, the addition of oblimersen to dacarbazine yielded a trend toward improve
29                              The addition of oblimersen to fludarabine plus cyclophosphamide signific
30                                              Oblimersen was administered at doses ranging from 3 to 7
31 ients who remained sensitive to fludarabine, oblimersen was associated with a four-fold increase in t
32                                              Oblimersen was associated with slightly more grade 3 to
33                                              Oblimersen was frequently associated with thrombocytopen
34                         We evaluated whether oblimersen would improve response to chemotherapy in pat